These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9269642)

  • 41. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
    Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
    J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.
    Nagano N; Miyata S; Abe M; Kobayashi N; Wakita S; Yamashita T; Wada M
    Kidney Int; 2006 Feb; 69(3):531-7. PubMed ID: 16395276
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients.
    Collins AJ; St Peter WL; Dalleska FW; Ebben JP; Ma JZ
    Clin Nephrol; 2000 Oct; 54(4):334-41. PubMed ID: 11076110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sevelamer, a phosphate-binding polymer, is a non-absorbed compound.
    Plone MA; Petersen JS; Rosenbaum DP; Burke SK
    Clin Pharmacokinet; 2002; 41(7):517-23. PubMed ID: 12083979
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
    Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
    Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hyperphosphatemia and phosphate binders.
    Schucker JJ; Ward KE
    Am J Health Syst Pharm; 2005 Nov; 62(22):2355-61. PubMed ID: 16278327
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Length of interdialytic interval influences serum calcium and phosphorus concentrations.
    Sigrist MK; Devlin L; Taal MW; Fluck RJ; McIntyre CW
    Nephrol Dial Transplant; 2005 Aug; 20(8):1643-6. PubMed ID: 15870223
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of new phosphate binders for chronic renal failure.
    Loghman-Adham M
    Drug Saf; 2003; 26(15):1093-115. PubMed ID: 14640773
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
    Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis.
    Nolan CR; Qunibi WY
    Kidney Int Suppl; 2005 Jun; (95):S13-20. PubMed ID: 15882308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phosphate binding assay for sevelamer hydrochloride by ion chromatography.
    Mazzeo JR; Peters RM; Hanus MR; Chen X; Norton KA
    J Pharm Biomed Anal; 1999 May; 19(6):911-5. PubMed ID: 10698557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sevelamer therapy for pediatric end-stage renal disease.
    Storms LE; Chicella MF; Dice JE
    Pharmacotherapy; 2006 Mar; 26(3):410-3. PubMed ID: 16503722
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sevelamer hydrochloride binds phosphate released from phytate in chicks fed 1α-hydroxy cholecalciferol.
    Bobeck EA; Meyer KM; Helvig C; Petkovich M; Cook ME
    J Ren Nutr; 2013 Jan; 23(1):21-7. PubMed ID: 22406121
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and acceptability of the new oral phosphate binder Lenziaren(®) in healthy cats fed a renal diet.
    King JN; Delport PC; Luus HG; Erasmus HL; Barnes PM; Speranza C
    J Vet Pharmacol Ther; 2015 Jun; 38(3):278-89. PubMed ID: 25363785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J; Piecha G; Kokot F; Wiecek A
    J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.
    Autissier V; Damment SJ; Henderson RA
    J Pharm Sci; 2007 Oct; 96(10):2818-27. PubMed ID: 17497733
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.
    Behets GJ; Dams G; Damment SJ; Martin P; De Broe ME; D'Haese PC
    Am J Physiol Renal Physiol; 2014 Jan; 306(1):F61-7. PubMed ID: 24197066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.